A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): Treatment rationale and study design

Clinical Lung Cancer

Volumn 13, Issue 6, 2012, Pages 505-509

  Garon, Edward B ^a   Cao, Dachuang ^b   Alexandris, Ekaterine ^b   John, William J ^b   Yurasov, Sergey ^b   Perol, Maurice ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

NSCLC; Previously treated; Ramucirumab; VEGF

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; PLACEBO; PLATINUM; RAMUCIRUMAB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; LUNG NEOPLASMS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84867503535     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.06.007     Document Type: Article

References (26)

1. H.M. Verheul, H.M. Pinedo The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors Clin Breast Cancer 1 1 Suppl 2000 S80 S84
2. D. Mukhopadhyay, K. Datta Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors Semin Cancer Biol 14 2004 123 130
3. H.P. Gerber, N. Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 2005 671 680
4. J. Folkman Antiangiogenesis agents V.T. DeVita, S.M.D. Hellman, S.A. Rosenberg, Cancer: Principles and Practice of Oncology 2005 Lippincott Williams & Wilkins Philadelphia, PA 2865 2882
5. R.K. Jain, D.G. Duda, J.W. Clark Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 2006 24 40
6. S.V. Ulahannan, J.R. Brahmer Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer Cancer Invest 29 2011 325 337
7. 1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 2010 780 787
8. A. Sandler, R. Gray, M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
9. D. Planchard Bevacizumab in non-small-cell lung cancer: a review Expert Rev Anticancer Ther 11 2011 1163 1179
10. A.B. Lima, L.T. Macedo, A.D. Sasse Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis PLoS One 6 2011 e22681
11. M. Skobe, P. Rockwell, N. Goldstein Halting angiogenesis suppresses carcinoma cell invasion Nat Med 3 1997 1222 1227
12. M. Prewett, J. Huber, Y. Li Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors Cancer Res 59 1999 5209 5218
13. C.J. Bruns, W. Liu, D.W. Davis Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases Cancer 89 2000 488 499
14. P. Sweeney, T. Karashima, S.J. Kim Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production Clin Cancer Res 8 2002 2714 2724
15. J.A. Garcia, G.R. Hudes, T.K. Choueiri Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/NCT00515697) Genitourinary Cancers Symposium Proceedings March 5-7 2010 Abstract 326
16. R. Garcia-Carbonero, F. Rivera, J. Maurel A phase 2, open label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) CP12-0709/NCT00862784 J Clin Oncol 30 Suppl 4 2012 Abstract 533
17. M. Hussain, D. Rathkopf, G. Liu A phase 2 randomized study of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy J Clin Oncol 30 Suppl 5 2012 Abstract 97
18. L.T. Vahdat, K. Miller, J.A. Sparano Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy J Clin Oncol 29 Suppl 2011 Abstract TPS151
19. D.R. Camidge, M.S. Ballas, S. Dubey A phase 2, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small cell lung cancer J Clin Oncol 28 Suppl 2010 Abstract 7588
20. J. Mackey, K. Gelmon, M. Martin TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer Clin Breast Cancer 9 2009 258 261
21. E. De Maio, C. Tibaldi, A. D'Incecco Consequences of targeted treatments for second-line therapy Ann Oncol 21 Suppl 7 2010 vii234 vii240
22. F.A. Shepherd, J. Dancey, R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
23. A.B. Sandler, J.H. Schiller, R. Gray Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab J Clin Oncol 27 2009 1405 1412
24. L. Crinò, E. Dansin, P. Garrido Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study Lancet Oncol 11 2010 733 740
25. P.J. Hollen, R.J. Gralla, M.G. Kris Quality of life during clinical trials: conceptual model for the lung cancer symptom scale (LCSS) Support Care Cancer 2 1994 213 222
26. EuroQoL Group EuroQol-a new facility for the measurement of health-related quality of life The EuroQol Group Health Policy 16 1990 199 208